AEWS1221: Randomized Phase II Trial Evaluating the Addition of the IGF-IR Monoclonal Antibody Gantitumab (AMG 479, NSC# 75008, IND# 120449) to Multiagent Chemotheraapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma.

Protocol: 
AAAO8855
Phase: 
II

AEWS1221: Randomized Phase II Trial Evaluating the Addition of the IGF-IR Monoclonal Antibody Gantitumab (AMG 479, NSC# 75008, IND# 120449) to Multiagent Chemotheraapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma.

Are you Eligible? (Inclusion Criteria)

-Subjects up to 50 years of age are eligible for this study.
-Patients with newly diagnosed Ewing sarcoma or peripheral primitive
neuroectodermal tumor (PNET) arising from bone or soft tissue and with
metastatic disease involving lung, bone, bone marrow, or other metastatic site.
-Patients must also meet all eligibility criteria as outlined in the study
protocol.

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States